{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:26:55Z","timestamp":1770218815175,"version":"3.49.0"},"reference-count":45,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T00:00:00Z","timestamp":1468022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Polish Ministry of Science and Higher Education","award":["N402 268836"],"award-info":[{"award-number":["N402 268836"]}]},{"name":"Healthy Ageing Research Centre","award":["REGPOT-2012-2013-1, 7FP"],"award-info":[{"award-number":["REGPOT-2012-2013-1, 7FP"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Aim: Find changes in matrix metallopeptidase-9 (MMP-9) levels during augmentation of antipsychotic treatment with sarcosine and a relationship between schizophrenia symptoms severity and initial level of MMP-9. Method: Fifty-eight patients with diagnosis of schizophrenia with predominant negative symptoms participated in a six-month prospective RCT (randomized controlled trial). The patients received two grams of sarcosine (n = 28) or placebo (n = 30) daily. At the beginning, after six weeks and after six months MMP-9 levels were measured. Severity of symptomatology was assessed with the Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale for Schizophrenia (CDSS). Results: MMP-9 serum levels were stable after six weeks and six months in both groups. We noted improvement in negative symptoms, general psychopathology and total PANSS score in sarcosine group compared to placebo; however, there was no correlations between serum MMP-9 concentrations and PANSS scores in all assessments. Initial serum MMP-9 concentrations cannot be used as an improvement predictor acquired during sarcosine augmentation. Conclusions: Our results indicate that either MMP-9 is not involved in the N-methyl-d-aspartate (NMDA)-dependent mechanism of sarcosine action in terms of clinical parameters or sarcosine induced changes in peripheral MMP-9 concentrations cannot be detected in blood assessments.<\/jats:p>","DOI":"10.3390\/ijms17071075","type":"journal-article","created":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T09:47:19Z","timestamp":1468230439000},"page":"1075","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study)"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8559-1078","authenticated-orcid":false,"given":"Dominik","family":"Strzelecki","sequence":"first","affiliation":[{"name":"Department of Affective and Psychotic Disorders, Medical University of \u0141\u00f3d\u017a, Central Clinical Hospital, Czechos\u0142owacka 8\/10, 92-216 \u0141\u00f3d\u017a, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Ka\u0142u\u017cy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Affective and Psychotic Disorders, Medical University of \u0141\u00f3d\u017a, Central Clinical Hospital, Czechos\u0142owacka 8\/10, 92-216 \u0141\u00f3d\u017a, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justyna","family":"Szyburska","sequence":"additional","affiliation":[{"name":"Department of Affective and Psychotic Disorders, Medical University of \u0141\u00f3d\u017a, Central Clinical Hospital, Czechos\u0142owacka 8\/10, 92-216 \u0141\u00f3d\u017a, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6159-6579","authenticated-orcid":false,"given":"Adam","family":"Wysoki\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Old Age Psychiatry and Psychotic Disorders, Medical University of \u0141\u00f3d\u017a, Central Clinical Hospital, Czechos\u0142owacka 8\/10, 92-216 \u0141\u00f3d\u017a, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","article-title":"NMDA receptor hypofunction model of schizophrenia","volume":"33","author":"Olney","year":"1999","journal-title":"J. Psychiatr. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0165-0173(99)00050-8","article-title":"Network interactions in schizophrenia\u2014Therapeutic implications","volume":"31","author":"Carlsson","year":"2000","journal-title":"Brain Res. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0893-133X(01)00243-3","article-title":"Effects of ketamine in normal and schizophrenic volunteers","volume":"25","author":"Lahti","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0893-133X(94)00131-I","article-title":"Subanesthetic doses of ketamine stimulate psychosis in schizophrenia","volume":"13","author":"Lahti","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11586650-000000000-00000","article-title":"Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia","volume":"25","author":"Singh","year":"2011","journal-title":"CNS Drugs"},{"key":"ref_6","first-page":"183","article-title":"Glutamatergic transmission alterations in schizophrenia","volume":"12","author":"Strzelecki","year":"2003","journal-title":"Post. Psychiatr. Neurol."},{"key":"ref_7","first-page":"193","article-title":"Glycine and its role in treatment of schizophrenia","volume":"12","author":"Strzelecki","year":"2003","journal-title":"Post. Psychiatr. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2004.05.005","article-title":"Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis","volume":"72","author":"Tuominen","year":"2005","journal-title":"Schizophr. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/978-3-642-25758-2_12","article-title":"Glycine Transport Inhibitors in the Treatment of Schizophrenia","volume":"Volume 213","author":"Javitt","year":"2012","journal-title":"Novel Antischizophrenia Treatments"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1002\/jnr.21273","article-title":"Matrix metalloproteinases in brain development and remodeling: Synaptic functions and targets","volume":"85","author":"Ethell","year":"2007","journal-title":"J. Neurosci. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/sj.cdd.4402141","article-title":"Matrix metalloproteinase-9 in glutamate-dependent adult brain function and dysfunction","volume":"14","author":"Michaluk","year":"2007","journal-title":"Cell Death Differ."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ceb.2004.07.010","article-title":"Regulation of matrix biology by matrix metalloproteinases","volume":"16","author":"Mott","year":"2004","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"21491","DOI":"10.1074\/jbc.274.31.21491","article-title":"Matrix metalloproteinases","volume":"274","author":"Nagase","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev.cellbio.17.1.463","article-title":"How matrix metalloproteinases regulate cell behavior","volume":"17","author":"Sternlicht","year":"2001","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1152\/jn.00202.2007","article-title":"In vivo roles for matrix metalloproteinase-9 in mature hippocampal synaptic physiology and plasticity","volume":"98","author":"Bozdagi","year":"2007","journal-title":"J. Neurophysiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrn3320","article-title":"Synaptic circuit remodelling by matrix metalloproteinases in health and disease","volume":"13","author":"Huntley","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1523\/JNEUROSCI.4359-05.2006","article-title":"Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory","volume":"26","author":"Nagy","year":"2006","journal-title":"J. Neurosci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.biopsych.2006.09.012","article-title":"TIMP-1 abolishes MMP-9-dependent long-lasting long-term potentiation in the prefrontal cortex","volume":"62","author":"Okulski","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"19520","DOI":"10.1073\/pnas.0807248105","article-title":"Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately","volume":"105","author":"Wang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/jmg.2008.061796","article-title":"Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model","volume":"46","author":"Bilousova","year":"2009","journal-title":"J. Med. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1242\/jcs.090852","article-title":"Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology","volume":"124","author":"Michaluk","year":"2011","journal-title":"J. Cell Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/cercor\/10.10.981","article-title":"Dendritic anomalies in disorders associated with mental retardation","volume":"10","author":"Kaufmann","year":"2000","journal-title":"Cereb. Cortex"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.mcn.2012.03.005","article-title":"The dendritic tree and brain disorders","volume":"50","author":"Kulkarni","year":"2012","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nn.2741","article-title":"Dendritic spine pathology in neuropsychiatric disorders","volume":"14","author":"Penzes","year":"2011","journal-title":"Nat. Neurosci."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Domenici, E., Wille, D.R., Tozzi, F., Prokopenko, I., Miller, S., McKeown, A., Brittain, C., Rujescu, D., Giegling, I., and Turck, C.W. (2010). Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009166"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2174\/1381612811319060010","article-title":"MMP-9 inhibitors in the brain: Can old bullets shoot new targets?","volume":"19","author":"Kaczmarek","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jad.2012.07.019","article-title":"Increased serum matrix metalloproteinase-9 (MMP-9) levels in young patients during bipolar depression","volume":"146","author":"Rybakowski","year":"2013","journal-title":"J. Affect. Disord."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/YPG.0b013e32832080be","article-title":"Matrix metalloproteinase-9 gene modulates prefrontal cognition in bipolar men","volume":"19","author":"Rybakowski","year":"2009","journal-title":"Psychiatr. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.brainres.2010.02.072","article-title":"Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene in alcohol dependence: Family and case control study","volume":"1327","author":"Samochowiec","year":"2010","journal-title":"Brain Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2009.02.005","article-title":"Functional polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizophrenia","volume":"109","author":"Rybakowski","year":"2009","journal-title":"Schizophr. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neuroscience.2008.05.045","article-title":"High resolution in situ zymography reveals matrix metalloproteinase activity at glutamatergic synapses","volume":"158","author":"Gawlak","year":"2009","journal-title":"Neuroscience"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/schbul\/sbv036","article-title":"Matrix metalloproteinase-9 as a novel player in synaptic plasticity and schizophrenia","volume":"41","author":"Lepeta","year":"2015","journal-title":"Schizophr. Bull."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1523\/JNEUROSCI.5346-08.2009","article-title":"Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin \u03b21 signaling","volume":"29","author":"Michaluk","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cca.2009.02.013","article-title":"Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome","volume":"403","author":"Goncalves","year":"2009","journal-title":"Clin. Chim. Acta"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.psychres.2010.04.049","article-title":"Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia","volume":"187","author":"Chang","year":"2011","journal-title":"Psychiatry Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.neulet.2013.09.059","article-title":"Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine","volume":"556","author":"Yamamori","year":"2013","journal-title":"Neurosci. Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.psychres.2013.12.009","article-title":"A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia","volume":"215","author":"Niitsu","year":"2014","journal-title":"Psychiatry Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Shibasaki, C., Takebayashi, M., Itagaki, K., Abe, H., Kajitani, N., Okada-Tsuchioka, M., and Yamawaki, S. (2016). Altered serum levels of matrix metalloproteinase-2, -9 in response to electroconvulsive therapy for mood disorders. Int. J. Neuropsychopharmacol.","DOI":"10.1093\/ijnp\/pyw019"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1515\/cclm-2015-0212","article-title":"Relationship between matrix metalloproteinase-9 and oxidative stress in drug-free male schizophrenia: A case control study","volume":"54","author":"Devanarayanan","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/brain\/aws171","article-title":"Fluoxetine inhibits matrix metalloprotease activation and prevents disruption of blood-spinal cord barrier after spinal cord injury","volume":"135","author":"Lee","year":"2012","journal-title":"Brain"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0006-3223(98)00367-9","article-title":"A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia","volume":"45","author":"Goff","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1176\/ajp.156.1.145","article-title":"Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia","volume":"156","author":"Potkin","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome\u2014A new world-wide definition. A consensus statement from the international diabetes federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/7\/1075\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:25:46Z","timestamp":1760210746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/7\/1075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,9]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7]]}},"alternative-id":["ijms17071075"],"URL":"https:\/\/doi.org\/10.3390\/ijms17071075","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,9]]}}}